Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...

Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, ...

By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry.

I'd like to thank you for taking time to join us for Cibus' Fourth Quarter 2025 Financial Results and Business ...

Cibus, Inc. (NASDAQ:CBUS) Q4 2025 Earnings Call Transcript March 17, 2026 Cibus, Inc. beats earnings expectations. Reported EPS is $-0.06837, expectations were $-0.3525. Operator: Thank you for your ...

Greetings, and welcome to the ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this con ...

They aren’t exactly glamorous, but naked mole rats have genes that could mean feeling younger and living longer.

Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA ...

The commentary titled 'Establishing a Commercial Solution for Extremely Rare Genetic Diseases' was published in Nature Biotechnology Commentary coincides with draft guidance from the FDA outlining a ...

This episode of the Vet Blast Podcast presented by dvm360® educates listeners about the progression of myxomatous mitral valve disease using Vinnie, the 7-year-old Chihuahua, as a case study. In this ...

To understand the human genome, scientists focused on protein-coding genes and their functions for decades. This has given us invaluable knowledge... | Cell And Molecular Biology ...